The humoral leukocyte adherence inhibition in the discrimination among histologic types of lung cancer

Magdolna Horváth, B. Fekete, István Forrai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In an attempt to differentiate among histologic types of lung cancer, a modified humoral leukocyte adherence inhibition (H-LAI) assay was used. All types of lung cancer gave positive H-LAI indices against both homologous and autologous tumor extracts of the relevant histologic types. Positive H-LAI values were obtained even with unrelated tumor extracts. Cross-reactivity suggests that common antigen determinants or antigens of broad specificity play a role in the H-LAI assay.

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalOncology
Volume40
Issue number5
DOIs
Publication statusPublished - 1983

Fingerprint

Lung Neoplasms
Leukocytes
Antigens
Neoplasms

Keywords

  • Histologic specificity
  • Humoral leukocyte adhcrcnce inhibition
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The humoral leukocyte adherence inhibition in the discrimination among histologic types of lung cancer. / Horváth, Magdolna; Fekete, B.; Forrai, István.

In: Oncology, Vol. 40, No. 5, 1983, p. 326-331.

Research output: Contribution to journalArticle

Horváth, Magdolna ; Fekete, B. ; Forrai, István. / The humoral leukocyte adherence inhibition in the discrimination among histologic types of lung cancer. In: Oncology. 1983 ; Vol. 40, No. 5. pp. 326-331.
@article{a70454589d2c4f0b9d4ed04317fc4756,
title = "The humoral leukocyte adherence inhibition in the discrimination among histologic types of lung cancer",
abstract = "In an attempt to differentiate among histologic types of lung cancer, a modified humoral leukocyte adherence inhibition (H-LAI) assay was used. All types of lung cancer gave positive H-LAI indices against both homologous and autologous tumor extracts of the relevant histologic types. Positive H-LAI values were obtained even with unrelated tumor extracts. Cross-reactivity suggests that common antigen determinants or antigens of broad specificity play a role in the H-LAI assay.",
keywords = "Histologic specificity, Humoral leukocyte adhcrcnce inhibition, Lung cancer",
author = "Magdolna Horv{\'a}th and B. Fekete and Istv{\'a}n Forrai",
year = "1983",
doi = "10.1159/000225755",
language = "English",
volume = "40",
pages = "326--331",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - The humoral leukocyte adherence inhibition in the discrimination among histologic types of lung cancer

AU - Horváth, Magdolna

AU - Fekete, B.

AU - Forrai, István

PY - 1983

Y1 - 1983

N2 - In an attempt to differentiate among histologic types of lung cancer, a modified humoral leukocyte adherence inhibition (H-LAI) assay was used. All types of lung cancer gave positive H-LAI indices against both homologous and autologous tumor extracts of the relevant histologic types. Positive H-LAI values were obtained even with unrelated tumor extracts. Cross-reactivity suggests that common antigen determinants or antigens of broad specificity play a role in the H-LAI assay.

AB - In an attempt to differentiate among histologic types of lung cancer, a modified humoral leukocyte adherence inhibition (H-LAI) assay was used. All types of lung cancer gave positive H-LAI indices against both homologous and autologous tumor extracts of the relevant histologic types. Positive H-LAI values were obtained even with unrelated tumor extracts. Cross-reactivity suggests that common antigen determinants or antigens of broad specificity play a role in the H-LAI assay.

KW - Histologic specificity

KW - Humoral leukocyte adhcrcnce inhibition

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0020559107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020559107&partnerID=8YFLogxK

U2 - 10.1159/000225755

DO - 10.1159/000225755

M3 - Article

C2 - 6194487

AN - SCOPUS:0020559107

VL - 40

SP - 326

EP - 331

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -